A Phase I, Two-part, Open-label, Non-randomised Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Afabicin (Primary) ; Afabicin (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Debiopharm
- 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
- 15 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 09 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.